Summary Thalidomide is well documented as being an effective drug in the treatment of erythema nodosum leprosum (ENL). The mechanism of action of thalidomide in ENL as well as the pathogenesis of ENL are yet to be fully determined.
Accepted for publication 18 September 1991 Summary Thalidomide is well documented as being an effective drug in the treatment of erythema nodosum leprosum (ENL). The mechanism of action of thalidomide in ENL as well as the pathogenesis of ENL are yet to be fully determined.
Lepromatous leprosy patients experiencing ENL have been reported to have an increase in the ratio of CD4+ to CD8+ cells in their blood and ENL skin lesions. Thalidomide has been shown to cause a decrease in the ratio ofCD4+ to CD8 + lymphocytes in the blood of healthy males. This decrease was due to a significant reduction in the numbers of CD4+ lymphocytes and an apparent increase in the numbers of CD8 + lymphocytes.
In this study, thalidomide's effectiveness in halting chronic ENL and arresting a relapse into ENL was consistently associated with a decrease in the numbers of CD4 + lymphocytes in the blood of 2 male lepromatous leprosy patients.
Thalidomide, a-phthalimido-glutarimide, dramatically relieves the signs and symptoms of erythema nodosum leprosum (ENL), an acute inflammatory complication of lepromatous leprosy. How thalidomide acts on ENL, and what the pathogenesis of ENL is, has not yet been fully determined.
It has been suggested that ENL is caused by an imbalance in immunoregulatory T lymphocyte subsets.I,2 In association with the acute phase of ENL is an increase in the ratio of helper/inducer T cells (CD4 +) to suppressor/cytotoxic T cells (CD8 +) in peripheral blood.I,3,4 This imbalance in blood lymphocyte subpopulations seems to be 0305-75 1 8/92/063005 +07 SO 1.00 © Lepra unique to the ENL reactional patient and does not occur during quiescent lepromatous disease.
Tn a previous study, ingestion of 200 mg of thalidomide daily for 4 days caused a decrease in the ratio of Leu-3a monoclonal antibody positive (CD4 +) to Leu-2a monoclonal antibody positive (CD8 + ) lymphocytes in the blood of healthy males.s This decrease was due to a significant reduction in the percentage and absolute numbers of CD4 + cells and an apparent increase in the percentage and absolute numbers of CD8 + cells.
This observation in healthy males and the reported alterations in the proportions of CD4 + and CD8 + cells in patients with acute ENL prompted us to speculate that thalidomide's effectiveness in ENL may be associated with a change in the population of CD4 + or CD8 + cells in blood.s After receiving informed consent fr om two male Ethiopian patients with chronic ENL, we tested this hypothesis.
Materials and methods

PATIENTS
Patient No. 943 is a 33-year-old male Ethiopian. He is classified as lepromatous with chronic ENL (LLjENL) and had been under DDS monotherapy for 14 years before being referred to ALERT for recurring ENL. He was placed on high doses of c10fazimine without improvement and was then started on steroids. He responded to high doses of steroids, but ENL reoccurred when the steroids were reduced to below 20 mg daily. He was then started on thalidomide. Upon completion of a fo ur-day course of 400 mg of thalidomide daily, his condition improved. However, the ENL lesions reoccurred upon discontinuation of thalidomide and a similar course of treatment with thalidomide was re initiated . His condition improved. Thalidomide became unavailable and he was returned to maintenance doses of steroids and 100 mg daily of c1ofazimine. This regimen continued for approximately 3 months. Then, after giving informed consent, on 21 July 1989 therapy with steroids was discontinued. He progressively lapsed into ENL and on 24 July 1989 treatment with thalidomide was once again initiated. Thalidomide (Grunenthal GMBH, 5190 StolbergjRhld, Germany) was taken orally in doses of 100 mg every 12 hr for 3 days.
At the end of3 days' treatment the thalidomide was stopped, and the patient progressively relapsed into ENL-7 days after the thalidomide was stopped thalidomide therapy was re-initiated with oral doses of 100 mg every 12 hr for 3 days.
Patient No. 944 is a 31-year-old male Ethiopian. He is a known LL patient since 1987 and is currently under multidrug therapy. He was referred to ALERT because of recurring ENL. He was placed on high doses of c1ofazimine, but in vain. He responded to high doses of steroids (up to 60 mgjday) but ENL reoccurred on lowering the dose of steroids. He was on maintenance doses of steroids and doses of 100 mg daily of c1ofazimine. After giving informed consent, on 21 July 1989 therapy with steroids was discontinued. He lapsed into ENL and on 24 July 1989 treatment with thalidomide was initiated. His course of treatment with thalidomide was similar to that described for patient No. 943.
CELL SEPARA TlON
On four separate occasions 30 ml blood was drawn in the morning fr om each patient. Approximately 10 ml blood was given to the clinical laboratory for a complete blood count, assessment of the erythrocyte sedimentation rate, and the content ofhaemoglobin. The remaining blood was defibrinated by shaking with glass beads for 10-15 min. The defibrinated blood was centrifuged for 20 min at 450 x G. The serum was removed and the pellet was diluted in 3 volumes of saline and layered on Ficoll-Hypaque. After centrifugation at 400 x G for 35 min at 20°C the mononuclear cells were collected and washed using RPMI-1 640.
DETERMINA TION OF T-CELL PHENOTYPES
T-Iymphocyte phenotypes were determined using fluorescein-conjugated monoclonal antibodies, Leu-I (T-cells, CDS +), Leu-2a (cytotoxic/suppressor, CD8 +), Leu-3a (helper/inducer, CD4+) (Becton Dickinson, Sunnyvale, CA, USA). The fluorescence was amplified by using fluorescein-conjugated rabbit antimouse Ig (DAK OPATTS, a/s, Denmark). Absolute numbers of lymphocytes bearing a given cluster differentiation antigen (CD) were calculated fr om a product of (a) leukocyte counts, (b) percentage of lymphocytes fr om differential counts, and (c) percentage of mononuclear cells that fluoresced with a particular fluorescein-conjugated antibody.
Results
A consistent reduction in the numbers of CDS + and CD4 + lymphocytes was noted in both patients after effective treatment of their EN L with thalidomide whereas minimal changes in the numbers of CD8 + lymphocytes were observed ( Figure I ).
After the second 3-day regimen with thalidomide, both patient 943 and patient 944 remained free ofENL. After I month, they were discharged from the hospital. During the past year, the patients have been seen occasionally at ALERT. Neither of the two patients has relapsed with ENL.
Discussion
Clinically, ENL is characterized by fever and a sudden er uption of acute inflammatory lesions in areas harbouring large numbers of Mycobacterium leprae. Histologically, the hallmarks of ENL skin lesions are vascular necrosis, oedema, and inflammation with infiltrates of neutrophils affecting the entire dermis and subcutaneous fa t. 6 The factor(s) which cause the influx of neutrophils into lesions is unknown. Immune complexes and cell-mediated mechanisms have been implicated in ENL.2 A disturbance in immunoregulation by T-cells is thought to be a fundamental occurrence during ENL. Patients experiencing ENL have an augmented in vivo responsiveness to sensitizers like dinitrochlorobenzene7 and their lymphocytes in culture with mitogens increase in responsiveness.u.8 Lymphocytes fr om ENL reactional patients have also been shown to respond to M. leprae antigens in culture.8 Evidence for alterations in the numbers of lymphocytes expressing immunoregulatory molecules like CD4 and CD8 has accumulated fr om studies conducted on lymphocytes in the blood 1.3.4 and in the skin lesions9-'3 of lepromatous patients experiencing ENL. In studies conducted on blood lymphocytes, lepromatous patients during ENL showed an increase in the per cent of helper cells, a decrease in the per cent of suppressor cells and a significant increase in the helper: suppressor ratio. 1 . 4 In a study conducted in Ethiopia, Mshana et al .3 fo und ENL patients to have an increase in helper cells, a decrease in suppressor cells resulting in a high helper : suppressor ratio. Laal et al. 8 showed a relative increase in the per cent ofCD8 + cells in the blood ofENL patients in comparison with patients with stable lepromatous disease. Interestingly, these investigators also reported an in vitro Iymphoproliferation to M. /eprae antigens in lepromatous patients undergoing ENL reactions. Contrary to the above reports Modlin et al. 1 2 showed that the percentage or numbers of T-helper or T-suppressor cells in ENL patients did not differ significantly fr om controls or lepromatous patients without ENL.
The skin lesions of lepromatous patients without ENL have been shown to have an excess of CD8 + lymphocytes whereas CD4 + lymphocytes are prevalent in ENL skin lesions.9-1 1 A shift fr om CD8 + to CD4 + prevalence is also observed in patients fr om nonreactional LL to active ENL. 13 The transient emergence of an increase in the per cent of T-helper cells in both the blood and skin lesions during the acute phase of ENL suggest that a target site for thalidomide in ENL may be the T-helper cell. Modulation of T-helper cells by thalidomide as a means to arrest ENL has been proposed.14.'5 This speculation is also supported by the effectiveness of cyclosporin-A (CsA) in the treatment of ENL.14 While CsA affects several different cell types with immune potential, it consistently inhibits T helper cell function and a CD4 + lymphocytopenia is observed during treatment with high doses of the drug. '6 Studies by Aszalos et al. '7 showed that the membrane potential of CD4 + lymphocytes was selectively affected in patients immunosuppressed with CsA. Vogelsang et al. ,'s using fluorescent-activated cell sorting, reported that a fluorescent bioactive derivative of CsA and a fluorescent hydroxylated product of thalidomide reacted with CD4 + and CD8 + lymphocytes.
Thalidomide may be able to alter the expression ofCD4 molecules by binding directly to them or reducing their density on the surface of lymphocytes or macrophages. Neither thalidomide nor its pH dependent hydrolysis products were able to bind directly to CD4 molecules and inhibit or reduce the intensity of fluorescence of mononuclear cells incubated with fluorescent-conjugated antibodies with specificity to CDS, CD4, and CD8. 19 The influence of thalidomide on de novo synthesis of CD4 molecules or internalization of CD4 molecules on lymphocytes and macrophages are being investi gated in our laboratory.
Interference with the expression of CD4 molecules by thalidomide could help explain many of the immunosuppressive properties ascribed to thalidomide. Thalidomide could also have additional sites of action as an immunosuppressive and anti-inflammatory drug in ENL. As examples, thalidomide has been shown to inhibit the production of TNF alpha by stimulated human monocytes.20 Thalidomide has been shown to inhibit TgM antibody synthesis.2 1 It has also been shown to stabilize lysosomal membranes fr om rat and human liver , has anti-inflammatory properties in carageen an rat paw oedema, antagonizes certain of the chemical mediators of inflammation (histamine, serotonin, prostaglandin E 2 and F 2 alpha) and inhibits the chemotaxis of neutrophils.22 L'efficacite de la thalidomide contre l'erythema nodosum leprosum est associee a une diminution des cellules CD4 + du sang peripherique E J SHANNON, MESTAWAT EJlGU, H S HAILE-MIRIAM, TEBEBE YEMANE BERHAN y GENET T ASESSE Resume Bon nombre de documents ont prouve I'efficacite de la thalidomide dans Ie traitement de I'erythema nodosum leprosum (ENL). Le mecanisme de I'action de la thalidomide contre I'ENL ainsi que la pathogenese de I'ENL sont encore a demontrer.
On a decele chez les patients atteints de Jepre lepromateuse sous la forme erythema nodosum leprosum un rapport plus eleve entre les cellules CD4+ et CD8+ dans Ie sang, ainsi que des lesions cutanees d'erythema nodosum leprosum. On a demontre que la thalidomide provoque une diminution du rapport entre les lymphocytes CD4+ et CD8+ dans Ic sang chez dcs subjets males sains. Cette diminution est due a une importante reduction du nombre des lymphocytes CD4+ et une augmentation apparente du nombre des lymphocytes CD8 +.
Dans cette etude, conduite chez deux patients males atteints de lepre lepromateuse, on constate une correlation entre I'efficacite de la thalidomide prescrite pour stopper I'erythema nodosum leprosum chronique et empecher une recidive de I'ENL et la diminution du nombre de lym phocytes CD4+ dans Ie sang.
Se asocia la efectividad de la Talidomida en el eritema nodosum leprosum con una reduccion de ceIulas CD4 + en la sangre periferica E J SHAN NON, MESTAWAT EJlGU, H S HAILE-MIRIAM, TEBEBE YEMANE BERHAN y GENET T ASESSE Resumen Se ha documentado bien la Talidomida como una droga efectiva en el tratamiento de eritema nodosum leprosum (ENL). Falta todaviva determinar completamente el mecanismo de actuacion de la Talidomida en el ENL, como tambien la patogenesis de l ENL.
Se ha informado que les pacientcs con lepra lepromatosa que padecen de ENL presentan un aumento de la relacion de celulas CD4 + a CDS + en la sangre y las lesiones cut{lIleas EN L. Se ha mostrado que la Talidomida causa una reduccion de la relacion de Iinfocitos CD4+ a CD8 + en la sangre de los hombres sanos. Esta reduccion se debe a una reduccion significativa de Iinfocitis CD4+ y un aparente aumento de linfocitos CDS +.
En este estudio, la efectividad de la Talidomida en parar el EN L cronico y detener una recaida de EN L, fue asociada constantemente con una reduccion en el numero de Iinfocitos CD4+, en la sangre de los hombres pacientes de lepra lepromatosa .
